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Comparison of the Effects of Carvedilol and
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the “Patient Journey”) in Patients With Heart Failure
Report From the Carvedilol Or Metoprolol European Trial (COMET)
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OBJECTIVES This study was designed to investigate the loss of well-being, in terms of life-years, overall and
in patients randomized to metoprolol versus carvedilol in the Carvedilol Or Metoprolol
European Trial (COMET).
BACKGROUND The ultimate objectives of treating patients with heart failure are to relieve suffering and
prolong life. Although the effect of treatment on mortality is usually described in trials, the
effects on patient well-being throughout the trials’ courses are rarely reported.
METHODS A total of 3,029 patients randomized in the COMET study were included in the analysis.
“Patient journey” was calculated by adjusting days alive and out of hospital over four years
using a five-point score completed by the patient every four months, adjusted according to the
need for intensification of diuretic therapy. Scores ranged from 0% (dead or hospitalized) to
100% (feeling very well).
RESULTS Over 48 months, 17% of all days were lost through death, 1% through hospitalization, 23%
through impaired well-being, and 2% through the need for intensified therapy. Compared
with metoprolol, carvedilol was associated with fewer days lost to death, with no increase in
days lost due to impaired well-being or days in hospital. The “patient journey” score improved
from a mean of 54.8% (SD 26.0) to 57.4% (SD 26.3%) (p  0.0068).
CONCLUSIONS Despite treatment with beta-blockers, heart failure remains associated with a marked
reduction in well-being and survival. Loss of quality-adjusted life-years through death and
poor well-being seemed of similar magnitude over four years, and both were much larger than
the loss that could be attributed to hospitalization. (J Am Coll Cardiol 2006;47:1603–11)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.069© 2006 by the American College of Cardiology Foundation
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tdeally, a treatment for heart failure (HF) should reduce
ortality, prevent or shorten hospitalization, improve well-
eing, and reduce the need for intensification of treatment.
owever, these are competing outcomes. In clinical trials,
n excess of death in one group may reduce non-fatal
orbid events and days in hospital because patients are
xposed to less overall time at risk (1). Moreover, treatments
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ccepted November 16, 2005.hat reduce mortality often selectively exert a greater abso-
ute reduction in mortality amongst the sickest patients,
See page 1612
ho report more symptoms and have a higher rate of
orbid events. This will introduce bias into the assessment
f non-fatal outcomes, leading to an underestimate of the
rue effects of therapy (1,2). An effect of treatment on
ymptoms may also be obscured if there is more intensifi-
ation of treatment for symptoms in one group (1).
One way around the inadequacy of single measures to
escribe the effects of treatment is to measure clinical
omposite outcomes (1–3), but these can be difficult to
nterpret and misleading (2). Time to first-event analysis for
eath or hospitalization has become popular because it
ncreases the event rate and therefore potentially increases
he power of the study, thus enabling the detection of
maller differences in effect or allowing the study size to be
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The COMET Study: The Patient Journey April 18, 2006:1603–11educed (4–9). Such composites can be analyzed using
onventional survival-type analyses, but ignore all events
including death) after the first event, give preferential
mphasis to minor events (because these occur more fre-
uently and therefore usually earlier than major ones), and
o not incorporate information on the patients’ day-to-day
ell-being. In such analyses, a brief admission to a hospital
ith atypical chest pain in the first month carries greater
tatistical significance than a major stroke or death in the
econd month. Therefore, such composite measures imper-
ectly reflect the patients’ experience of their illness and its
odification by therapy.
An alternative way to combine data is to use all the
vailable information to produce a composite of days alive
nd out of hospital adjusted for well-being and the need for
ntensification of therapy (1,10). This has been termed the
patient journey” (1) and is close in concept to quality-
djusted life-years (11), a tool commonly used for health
conomic analyses. This type of analysis can be used to
valuate both the effects of treatment and the unmet needs
f patients.
The Carvedilol Or Metoprolol European Trial (COMET)
6,12,13) compared the effects of carvedilol and metoprolol on
orbidity and mortality. Serial data on symptoms, patient
ell-being, and hospitalization were collected, in addition
o mortality, allowing the “patient journey” and its individ-
al components to be assessed in patients receiving contem-
orary therapy for the first time in a large study.
ETHODS
he COMET study was an international, multi-center,
andomized (1:1), double-blind, parallel group trial com-
aring the effect of carvedilol and metoprolol tartrate on
orbidity and mortality in patients with chronic HF.
etailed descriptions of the study design, baseline charac-
eristics, and results have been published (12).
atients. The main inclusion criteria were the presence of
hronic symptomatic New York Heart Association (NYHA)
unctional class II to IV HF, left ventricular ejection fraction
35%, at least one cardiovascular hospitalization during the
revious two years, receiving stable HF treatment with
ngiotensin-converting enzyme inhibitors for at least four
eeks unless contraindicated, and receiving treatment with
iuretics (40 mg of furosemide or equivalent) for at least
wo weeks. Patients with a contraindication to a beta-
locker, uncontrolled hypertension, major valvular disease,
r a major vascular event or ventricular arrhythmia within
Abbreviations and Acronyms
COMET  Carvedilol Or Metoprolol European Trial
HF  heart failure
NYHA  New York Heart Associationhe previous two months were excluded. uThe study conformed to good clinical practice guidelines
nd followed the recommendations of the Declaration of
elsinki. The relevant, local ethics review boards approved
he protocol. Written informed consent was obtained in all
atients before enrolment.
rial procedures. At randomization, eligible patients
3,029) were assigned to receive either carvedilol (3.125 mg
wice daily) or metoprolol tartrate (5 mg twice daily). The
ose of each beta-blocker was increased to the target dose of
arvedilol (25 mg twice daily) or metoprolol (50 mg twice
aily) at two weekly intervals.
During the maintenance phase, patients were assessed
very four months. At each assessment, patients were
nvited to report the severity of their breathlessness, fatigue,
nd overall well-being using a simple five-point scale.
nvestigators recorded NYHA functional class and current
F medication. The reasons for and dates of admission and
ischarge were recorded for all hospitalizations and the date
f death if it occurred.
ethodology for construction of the “patient journey.” The
patient journey” comprises four major components that are
elevant to the patients’ experience: longevity, days in
ospital, well-being or symptoms, and the need for inten-
ification of diuretic therapy to control symptoms (13).
ssigning an arbitrary value to each component allows an
verall “patient journey” score to be calculated for each
atient. Each individual patient’s “journey” should be of
qual potential duration to other patients with whom their
utcome is being compared. Thus, outcome over one year,
wo years, three years, and four years is described. A large
umber of patients were not followed for more than four
ears, and therefore scores beyond four years were not
alculated.
eath and hospitalization. Patients were assigned a score
or each day alive and out of hospital. On the day that the
atient died and for every day thereafter, the patient was
ssigned a score of zero. Days spent in hospital were also
ssigned a zero score.
ell-being and symptoms. The primary analysis of inter-
st was conducted using a five-point scoring system asking
atients how well they felt every four months. Investigators
ere required to ask patients, “On a scale of one to five,
here one is very good and five is very poor, how have you
een feeling over the past week?” and instructed to take the
nswer given without trying to interpret or modify it. A
core of 100% was assigned for each day alive and out of
ospital if the patient reported feeling very good (“well-
eing” score 1). The score was reduced by 20% for each
ecrement in the patient-reported score down to a lowest
otential score of 20% (“well-being” score 5). Patients were
ssumed to have a health state that was the average of the
ssessment at the beginning and end of the four-month
eriod (effectively a “running mean”), with zero scores for
ays in hospital. If a patient was in hospital at the four-
onth assessment, the actual scored assessment was stillsed to calculate average “well-being.” If no assessment of
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April 18, 2006:1603–11 The COMET Study: The Patient Journeyell-being was reported at this time, the patient was
ssumed to be in the worst health state. If a patient died of
orsening HF during any follow-up period, it was assumed
hat they were in the worst health state on the day of death,
nd this was used to calculate average health state. If the
atient died of other causes (mainly sudden death), they
ere assumed to be in the same health state on the day of
eath as that last recorded. If a scheduled measurement of
ell-being was missed, average health state could be calcu-
ated using the next measurement and averaging over a
onger period. This included deaths.
A secondary analysis was performed using NYHA func-
ional class based on comparative data with a visual analogue
cale, the Ladder of Life questionnaire, used in the Studies
f Left Ventricular Dysfunction (SOLVD) study (14) and
ebased so that patients in NYHA functional class I were
eemed to have the best possible score (i.e., 100%). Thus,
YHA functional class I was ranked 100% (71% actual in
OLVD), NYHA functional class II 86% (61% actual),
YHA functional class III 73% (52% actual), and NYHA
unctional class IV 66% (47% actual).
Further analyses were conducted using different assump-
ions about patient well-being reflecting either the view that
urviving with poor well-being has a low value (“well-being”
cored as 100%, 90%, 70%, 30%, and zero) or that survival
egardless of health state has a high value (“well-being”
cored as 100%, 90%, 80%, 70%, and 60%). These analyses
llow the trial result to be viewed from different patient
erspectives. It is essential, in order to comprehend the
tility of the “patient journey,” to understand that it is the
iew of future patients not involved in the trial (external
erspective) rather than the “historical” patients who par-
icipated in the trial who should judge which values to
ssign to scores, because each individual patient is different
nd the patients to whom the data will be applied will rarely
e the individuals who participated in the study. Also, the
alue ascribed to living in different health states may change
ithin an individual patient over time.
ntensification of therapy. There are many reasons treat-
ent might be increased in patients with HF (1). Digoxin
ay have been given for atrial fibrillation. Angiotensin-
onverting enzyme inhibitor dose may have been increased
nd aldosterone antagonists introduced because of a per-
eived prognostic benefit rather than a change in the
atient’s status. On the other hand, there are few reasons to
ncrease the dose of a diuretic other than for worsening
ymptoms or signs, and the need for higher doses of diuretics
ndicates a worse prognosis. Addition of a loop diuretic to a
hiazide or vice versa or an increase in furosemide or
quivalent (furosemide 40 mg  bumetanide 1 mg 
orasemide 10 mg) by both 40 mg/day and by 50% was
aken as evidence of a need for intensified diuretic therapy.
hanges in diuretic therapy were assessed only at four-
onth intervals. If treatment had been increased, the
atient was assumed to be one rank worse than actually
cored at that time point, unless already in the worst rank,
h
An which case no penalty was applied. This effectively
ssumes that change in therapy occurred at the midpoint of
he interval assessed. Temporary changes in therapy that did
ot persist until a four-month assessment were ignored. A
enalty for increased diuretic therapy could be incurred only
nce, to allow for the fact that some clinicians might titrate
iuretic therapy gradually whereas others will make more
adical changes. Patients who had diuretic therapy reduced
o baseline levels lost any imposed penalty. Reduction of
iuretics to below baseline levels did not lead to improved
cores in this analysis.
tatistical design and analysis. The co-primary end points
f the study were all-cause mortality and the composite end
oint of all-cause mortality or all-cause hospitalization. All
our individual components of the “patient journey” were
econdary end points, including NYHA functional class,
umber and duration of hospitalizations, need for increased
iuretic therapy, and death. The concept of the “patient
ourney” outcome measure evolved during the course of the
tudy, and details were published before unblinding of the
tudy but were not a pre-specified outcome (1). Accord-
ngly, statistical analysis of this outcome should be consid-
red exploratory to assist in the design and interpretation of
uture studies. All randomized patients were included in the
able 1. Baseline Characteristics
Carvedilol
(n  1,511)
Metoprolol
(n  1,518)
ge (yrs) 61  11 62  11
ender (% male) 79 80
ystolic BP (mm Hg) 126  19 126  20
iastolic BP (mm Hg) 77  11 77  11
eart rate (beats/min) 81  13 81  14
YHA functional class
II 48 49
III 48 47
IV 3 4
etiology CHF*
Ischemic heart disease 51 54
Hypertension 18 18
Dilated cardiomyopathy 44 44
Previous valve surgery 3 2
VEF 26  7 26  7
iabetes 24 24
troke 7 7
trial fibrillation/flutter 21 19
oncomitant medication at randomization
Diuretics† 99 99
ACE inhibitors† 92 91
Angiotensin receptor antagonists 6 7
Digitalis 61 58
Antiarrhythmics 13 12
Nitrates 32 32
Aldosterone antagonists 11 11
Anticoagulants 48 44
Aspirin 35 39
Lipid-lowering agents (statins) 20 22
More than one answer possible; †Inclusion criteria. Values are mean  SD or %.
ACE  angiotensin-converting enzyme; BP  blood pressure; CHF  chroniceart failure; LVEF  left ventricular ejection fraction; NYHA  New York Heart
ssociation.
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The COMET Study: The Patient Journey April 18, 2006:1603–11nalysis using the intention-to-treat principle. It was
lanned that all patients would be followed to the end of the
tudy, even after permanent cessation of study treatment or
fter heart transplantation. Some patients were lost to
ollow-up or withdrew consent. These patients were cen-
ored at the last known date of contact or date of withdrawal
rom the trial. Using the methods in this study, a complete
patient journey” over four years could be calculated for 97%
f patients.
A descriptive analysis to show how key patient charac-
eristics affected the “patient journey” including gender, age
bove or below 65 years, NYHA functional class II, III, or
V, and left ventricular ejection fraction above or below 25%
as conducted. For mortality, Kaplan-Meier survival esti-
ates were calculated and differences assessed using Cox
roportional hazard models. Differences in continuous vari-
bles were assessed by t tests and by the chi-square test for
ategorical data. For each patient, a proportion of days lost
n each interval was calculated, and differences between the
reatment groups were assessed using t tests.
ESULTS
f 3,029 patients, 1,511 were assigned to treatment with
arvedilol and 1,518 to metoprolol. The mean study dura-
Table 2. Cumulative Distribution and Reason
Carvedilol Days
1 year
Potential days 551,515
Days lost to
Death 28,292
Hospitalization 9,738
Impaired well-being 151,115
Diuretic adjust 9,684
Total life lost 198,829
2 years
Potential days 1,103,030
Days lost to
Death 99,626
Hospitalization 18,043
Impaired well-being 281,565
Diuretic adjust 22,746
Total life lost 421,979
3 years
Potential days 1,654,545
Days lost to
Death 209,000
Hospitalization 25,234
Impaired well-being 398,673
Diuretic adjust 36,352
Total life lost 669,259
4 years
Potential days 2,206,060
Days lost to
Death 349,983
Hospitalization 31,658
Impaired well-being 508,431
Diuretic adjust 49,462
Total life lost 939,534Well-being score reported is base case. A 1% difference reflects ab
full health per patient.ion was 58 months. Five patients were lost to follow-up and
8 patients, one of whom underwent heart transplantation,
ithdrew their consent during the course of the study.
wenty-eight patients in the carvedilol group and 27
atients in the metoprolol group underwent heart transplan-
ation. The two treatment groups were similar with respect
o baseline characteristics and concomitant therapies at
ntry (Table 1).
ortality. A total of 512 deaths were recorded in patients
ssigned to carvedilol, compared with 600 deaths in those
ssigned to metoprolol (hazard ratio of 0.83; 95% confi-
ence interval 0.74 to 0.93, p  0.0017) (Table 2). Overall,
.4% of days of follow-up (59,954 days) were lost through
eath in the first year, increasing cumulatively to 17.0%
751,003 days) by the end of the 4th year.
ospitalization. The number of hospitalizations and hos-
ital days was similar during treatment with carvedilol and
etoprolol (Table 2). During the first year, patients spent
.8% of study days (20,220 days), and cumulatively over four
ears, 1.4% of study days in hospital (63,428 days) or 1.7%
f days alive.
ell-being and NYHA functional class. The baseline
istribution of well-being scores are shown in Figure 1,
ccording to NYHA functional class, age, and gender.
ays of Life Lost Over 4 Years
% Loss Metoprolol Days % Loss
554,070
5.1 31,662 5.7
1.8 10,482 1.9
27.4 153,526 27.7
1.8 10,706 1.9
36.1 206,376 37.2
1,108,140
9 111,623 10.1
1.6 18,043 1.6
25.5 287,901 26.0
2.1 24,104 2.2
38.3 441,671 39.9
1,662,210
12.6 234,139 14.1
1.5 25,082 1.5
24.1 410,428 24.7
2.2 37,857 2.3
40.4 707,506 42.6
2,216,280
15.9 401,020 18.1
1.4 31,770 1.4
23.0 517,218 23.3
2.2 51,138 2.3
42.6 1,001,147 45.2for Dout 22,000 days difference over 4 years, or about 15 days of
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April 18, 2006:1603–11 The COMET Study: The Patient Journeyatients with higher NYHA functional class and greater age
enerally had worse scores for well-being, but the distribu-
ion of scores was similar in men and women.
During the first year, patients spent 166,568 days in
ell-being state 4 or 5 (16% of days alive) and 383,391 days
37%) in NYHA functional class III or IV. Over four years,
16,608 days (17% of days alive) were spent in well-being
tate 4 or 5 and 1,272,527 days (35%) were spent in NYHA
unctional class III or IV (Table 2). Overall, 28% of days
304,641 days) were lost through impaired quality of life
uring the first year of follow-up and, cumulatively, 23%
1,025,649 days) during four years of follow-up using the
ase-case well-being score (Table 2). If only days alive are
ncluded, then 28% were lost to impaired well-being during
our years of follow-up.
djustment for increasing diuretic requirement. Adjust-
ent of quality-of-life scores because of increasing diuretic
Well-being Score: NYHA
0%
10%
20%
30%
40%
50%
60%
All Patients NYHA II NYHA III NYHA IV AG
Frequency
igure 1. Distribution of patients’ scoring of well-being on a scale of 1 (ve
ew York Heart Association (NYHA) functional class.
igure 2. Cumulative amount of time spent in each health state during di
live or dead. The difference between interventions was significant (p  0
pent out of hospital if the patient reported being very well (“well-being” score 1)
own to a lowest potential score of 20% (“well-being” score 5).equirements caused the loss of 1.8% (20,390 days) of days
n the first year and 2.3% (100,600 days) cumulatively over
our years using the well-being score and 1.0% (10,537) and
.2% (53,877 days) using scores based on NYHA functional
lass (Table 2). No differences between carvedilol and
etoprolol were identified.
verall composite score. Overall, patients lost 37% of
ays of life (405,205 days) in the first year and 44%
1,940,680 days) over four years after adjustment for
ell-being (base case) and treatment (Table 2). The
omposite outcome reflected mostly loss of quality of life
nitially, but mortality became a more important compo-
ent with long-term follow-up (Fig. 2). Days in hospital
nd adjustment of health state for increases in diuretics
ade a small contribution to the composite outcome. If
cores for NYHA functional class were substituted for the
ell-being score, days of life lost were 24% (266,072
 & Gender Compared
AGE 60-70 AGE >70 MALE FEMALE
Score = 1
Score = 2
Score = 3
Score = 4
Score = 5
d) to 5 (very poor) according to age, gender, and investigator-determined
t follow-up periods expressed as a proportion of potential days follow-up,
). For the base case, a score of 100% was assigned for each day alive and, Age
E <60
ry goofferen
.0068and was reduced by 20% for each decrement in the patient-reported score
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The COMET Study: The Patient Journey April 18, 2006:1603–11ays) in the first year and 33% (1,437,351 days) over four
ears.
Overall, compared to metoprolol, carvedilol reduced the
otal number of days lost over one year from 206,376 (37%)
o 198,829 (36%) in the first year and from 1,001,147 days
45%) to 939,534 (43%) over four years using base-case
ell-being scores (p  0.0068) (Fig. 2). However, mean
ifferences reflect the heterogeneity in outcome poorly. The
istribution by centiles of individual patient outcomes for
atients assigned to metoprolol and carvedilol is shown in
igure 3. Carvedilol shifted the distribution of outcomes
avorably (p  0.0068). From this distribution, it can be
alculated that one in every eight patients switched from
etoprolol to carvedilol would have an absolute improve-
ent of 10% in their “patient journey” score over four years,
otionally equivalent to an extra five months of full health.
igure 4 summarizes the effects of different assumptions
bout the value that should be assigned to well-being other
han the base-case assumption. One set of values (desig-
ated “well-being”) reflects the view that survival with poor
ell-being is of low value, another (designated “life”) the
iew that survival even with poor well-being has a high
alue. Finally, a set of assumptions based on NYHA functional
lass reported in the SOLVD trial is given. These show the
ort of variation and variation in difference between carve-
ilol and metoprolol that might be expected. The score was
naffected by the inclusion or exclusion of the few patients
ho received heart transplants.
utcomes in subgroups (Fig. 5). Men and women had
imilar overall “patient journey” scores, although loss
hrough death tended to be greater in men and loss of
ell-being greater in women. Older patients had worse
cores, owing entirely to a higher mortality. Patients with
igure 3. Distribution of percentages of notional days of life lost using the
patient journey” score. The best possible score is 0% loss (surviving 4 years
ith best well-being state, without increased need for diuretic therapy,
ospitalization, or death). Poor scores may reflect early death, persistently
oor well-being, or prolonged periods of hospitalization, or any combina-
ion of such events. Data shown use the base-case set of scores for
ell-being. Note the shift to the left in scores among patients randomized
o carvedilol compared to metoprolol (p  0.0068).ore severe symptoms at baseline also had worse overall
a
pcores, but mainly owing to higher mortality. Patients
nitially in NYHA functional class IV lost 39% of follow-up
ays to death, 2% to hospitalization, and 23% to poor
ell-being over four years, whereas patients initially in
YHA functional class II lost 12%, 1%, and 21% respec-
ively. Patients with lower left ventricular ejection fraction
ad slightly worse scores owing to a higher mortality, but
ot poorer well-being. Carvedilol appeared superior to
etoprolol in all groups of patients studied (Fig. 6).
ISCUSSION
his analysis of the COMET study suggests that a com-
osite outcome measure, such as the “patient journey,”
rovides a powerful, comprehensive measure of the benefits
f therapy and the still-unmet needs of patients with HF.
nlike conventional composite measures, it uses a large
mount of the available data and not just one potentially
isleading event. It is also a more robust measure of the
ffects of therapy on well-being because it does not depend
n a single evaluation that may be unrepresentative of the
verall effect of treatment and because it does not require
rbitrary conventions to deal with values that are lost
hrough the patient’s death.
Death and patient-evaluated well-being appear to be the
ajor factors that drive this outcome measure, whereas
ospitalization and adjustment attributable to the need for
ntensified therapy make relatively small contributions, at
east in the types of patients enrolled in the COMET study.
linical trials have emphasized the importance of reducing
ortality but have placed less emphasis on improving
atients’ symptoms, and have often used events such as
ospitalization, myocardial infraction, or stroke as a surro-
ate measure of symptoms or disability. Even though we
igure 4. Comparison of percentage of days alive lost due to poor well-being
n patients randomized to carvedilol or metoprolol using four different sets of
cores. Note that patients receiving carvedilol lived longer, and therefore
otential days lost to poor well-being while receiving carvedilol were higher
han for metoprolol. “Base case” represents well-being scores of 100, 80, 60, 40,
r 20. “Well-being” reflects the view that survival in a poor health state has low
alue (100, 90, 70, 30, 0). “Life” reflects the view that survival regardless of
ealth state has high value (100, 90, 80, 70, 60). “NYHA” reflects scores
erived from Glick et al. (14) (100, 86, 73, 66). AR absolute reduction with
1% difference reflecting about 200,000 days in study or about 15 days per
atient; RR  relative reduction.
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April 18, 2006:1603–11 The COMET Study: The Patient Journeyalued days lost through hospitalization the same as death,
hich some may consider too severe, it added relatively little
o the total loss of life-days. Even though hospitalization
ay be a very distressing event, most patients recover. It is
ore relevant to measure symptoms and disability rather
han to impute them from sparse events. This analysis
hows that simple, serial direct measures of patient well-
eing are feasible. This study also emphasizes that improv-
igure 5. Days lost, overall and by component of the “patient journey,”
ssociation (NYHA) functional class (C), and left ventricular ejection fra
igure 6. Overall days lost in subgroups of patients according to age,
ender, New York Heart Association (NYHA) functional class, and leftp
entricular ejection fraction (LVEF) in patients randomized to carvedilol or
etoprolol.ng patient well-being is an important unmet patient need
nd goal of therapy that has not been well reported in large
utcome studies, with few exceptions (7,15).
Compared to metoprolol tartrate, carvedilol reduced the
otal days lost. This effect was mostly due to increased
ongevity. Metoprolol tartrate has previously been shown to
mprove well-being after myocardial infarction (10) and in
atients with HF and dilated cardiomyopathy (16), indicat-
ng that the effect of carvedilol was in addition to that of an
ctive control. Overall, there was no difference between
reatments in loss of days to hospitalization or the need for
ntensified therapy. Thus, carvedilol did not increase the
urden of illness during the period that it extended life.
Quality-adjusted life-years are widely used as a measure
f the utility of treatment in health economic analyses. The
patient journey” outcome measure is a similar concept, but
lso incorporates key health-economic data such as the time
pent in hospital. Some might desire a more formal and
engthy tool for the assessment of well-being. However,
btaining complete records repeatedly can be difficult using
any quality-of-life tools (15). We opted for a simple tool
hat could be obtained reliably, at relatively frequent inter-
als, and without exhausting the patience of investigator or
bgroups of patients according to gender (A), age (B), New York Heart
(D).atient. Frequent, repetitive assessment avoids undue
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The COMET Study: The Patient Journey April 18, 2006:1603–11eight being given to solitary events, such as an accident,
ereavement, the weather, or a visit from a friend, which
ay have relatively short-lived effects on how patients feel.
alidation of the patient well-being score against more
ormal quality-of-life instruments would be desirable, but
uality of life and well-being are simple, subjective measures.
ore complex means of assessment are mainly targeted at
dentifying why quality of life is impaired, which is of
econdary importance in the context of a large randomized
ontrolled study.
Patient well-being scores were related to NYHA func-
ional class, as might be anticipated (13), although the
elationship was not perfect, as has been shown in other
rials (17,18). The NYHA functional class is assigned by an
nvestigator and reflects their view of the patient’s functional
apacity, which may be biased by knowledge about cardiac
unction and physical frailty as well as the need to fulfill
ntry criteria for clinical trials. Patient well-being score
eflects the patient’s view of their symptoms and health and
ill be modified by the patient’s emotional state and the
egree to which they have adapted to their illness and
ymptoms. It is therefore not surprising that there is only a
oderate relationship between these scores.
The estimated loss of quality of life by using NYHA
unctional class was less than that suggested by patient
ell-being score. This mainly reflected the values attached
o the different scoring systems rather than differences in the
core assigned. Thus the worst NYHA functional class was
alued as 66% of full quality of life, versus a value of only
0% for the poorest well-being score. However, regardless
f which measure was used, the pattern of results was
imilar. Assigning a numerical value to an indicator of
ell-being or quality of life is arbitrary, and different
ssumptions can markedly alter the “amount” of life lost
wing to poor health compared with that lost through
eath. However, we used a range of assumptions to reflect
ifferent patient-views of the relative importance of survival
ersus quality of life that allows the trial data to be valued
rom the perspective of patients, carers, and physicians who
re deciding on the utility of the intervention for their own
uture or their patients.
Despite worse well-being scores among patients with
ore severe HF at baseline, overall loss of days owing to
oor well-being was remarkably similar in patients with
YHA functional classes II, III, and IV. This reflects the
act that overall loss of well-being reflects both the severity
f disease and the duration of exposure. This suggests that
he “patient journey” is best suited to assessing treatments
hat alter both well-being and prognosis. This outcome
easure is likely to be less robust when used to assess
reatments for HF that reduce only mortality. If only
ortality is considered, the patient effectively counts as 0%
f dead and 100% if alive, whereas when using the “patient
ourney” relatively few days alive are scored as 100%.
Many refinements could be added to the model, includ-
ng the validation of simple instruments to measure well-eing, formal measurement of quality of life in either a
ubgroup of patients or on all patients on a few occasions,
nd the application of discounting, so that life in the early
art of the trial is valued more highly. None of these was
rospectively planned in this study, but they could be
ncorporated into future studies.
In conclusion, the proposed outcome measure, “patient
ourney,” appears to be a useful single measure to assess the
ffects of treatment on symptoms, morbidity, and mortality.
he concept would benefit from the use of formal validation
f the well-being scores used in this study or the use of an
lready validated tool. “Patient journey” is improved by
arvedilol compared to metoprolol tartrate, mainly owing to
reduction in mortality but, importantly, the mortality
enefit did not result in more people staying alive in a very
oor health state. It is clear that there is still much room for
mprovement in the treatment of HF.
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